Type 2 Diabetes
Conditions
Interventions
Group A
patients who take Linagliptin
Group B
patients who take Voglibose
Sponsors
Japan society of Patient Reported Outcome
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with type 2 diabetes have not been taken antidiabetic medication more than 12 week. 2.7.4% and higher -HbA1c- under 10% (NGSP) at screening. 3.18 over - BMI under 30 4.eGFR,45 or higher 5.Twenty years of age or older, regardless of gender 6.Written consent for participation in the study
Exclusion criteria
Exclusion criteria: 1.Type 1 and secondary diabetes 2.Severe infectious disease, before or after surgery, and severe trauma 3.Events of myocardial infarction, cerebral stroke, cerebral infarction and TIA in the past 3 month. 4.Moderate or severer heart failure(NYHA/New York Heart Association stage III or severer) 5.Severe liver dysfunction (ALT,AST and ALP face 3 times the normal level) 6.Past medical history of hypersensitivity to investigational drugs. 7.Patients addicted to alcohol and drugs. 8.Pregnant, lactating, and possibly pregnant women and those planning to become pregnant. 9.Patients with cancer. 10.Patent receiving steroid therapy with inflammatory affection. 11.Past medical history of abdominal operation and ileus. 12.Judged as ineligible by clinical investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of mean 24 hours glucose level at the point of 12 weeks from Baseline | — |
Countries
Japan
Contacts
Public ContactHiroki Takyama
Soiken.inc Division of clinical study support
Outcome results
None listed